This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author. This makes it the first identity verification and compliance platform to ...

For patients with acute myeloid leukemia (AML) who are 75 years of age or older or who are ineligible for intensive induction chemotherapy, azacitidine or decitabine plus venetoclax is the standard of ...

U.S. clearing giant DTCC picked Stellar as the first public blockchain to connect to its upcoming tokenized securities settlement platform. The partnership builds on an almost decade-long partnership ...

The new solution helps e-commerce, gig and service marketplaces protect customers, revenue and reputation Sumsub for Marketplaces combines identity and business verification, behavioral analytics and ...

The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy. The combination of decitabine-cedazuridine ...

Crypto compliance demand is surging as AI fraud evolves faster than firms can respond, Sumsub CEO Andrew Sever says. Crypto compliance firms are reporting a sharp rise in demand as AI fraud attacks ...

Building on consistent Chartis recognition across fincrime, identity, and compliance reports for the third consecutive year Chartis Research is a leading provider of research and analysis on the ...

Shin Huyn-song, the nominee to become governor of the Bank of Korea, is prioritizing a potential central bank digital currency and bank deposit tokens over privately issued stablecoins. Shin said he ...

FinCEN has proposed reforming AML/CFT programs to reduce compliance burdens and focus on effectiveness rather than paperwork. The rule would give institutions more flexibility in risk-based design and ...

This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author. The partnership embeds Sumsub’s globally scalable identity verification ...